ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1.
Epithelial to mesenchymal transition (EMT), and the reverse mesenchymal to epithelial transition (MET), are known examples of epithelial plasticity that are important in kidney development and cancer metastasis. Here we identify ASPP2, a haploinsufficient tumour suppressor, p53 activator and PAR3 bi...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado: |
Nature Publishing Group
2014
|
| _version_ | 1826297681160437760 |
|---|---|
| author | Wang, Y Bu, F Royer, C Serres, S Larkin, JR Soto, MS Sibson, N Salter, V Fritzsche, F Turnquist, C Koch, S Zak, J Zhong, S Wu, G Liang, A Olofsen, P Moch, H Hancock, D Downward, J Goldin, R Zhao, J Tong, X Guo, Y Lu, X |
| author_facet | Wang, Y Bu, F Royer, C Serres, S Larkin, JR Soto, MS Sibson, N Salter, V Fritzsche, F Turnquist, C Koch, S Zak, J Zhong, S Wu, G Liang, A Olofsen, P Moch, H Hancock, D Downward, J Goldin, R Zhao, J Tong, X Guo, Y Lu, X |
| author_sort | Wang, Y |
| collection | OXFORD |
| description | Epithelial to mesenchymal transition (EMT), and the reverse mesenchymal to epithelial transition (MET), are known examples of epithelial plasticity that are important in kidney development and cancer metastasis. Here we identify ASPP2, a haploinsufficient tumour suppressor, p53 activator and PAR3 binding partner, as a molecular switch of MET and EMT. ASPP2 contributes to MET in mouse kidney in vivo. Mechanistically, ASPP2 induces MET through its PAR3-binding amino-terminus, independently of p53 binding. ASPP2 prevents β-catenin from transactivating ZEB1, directly by forming an ASPP2-β-catenin-E-cadherin ternary complex and indirectly by inhibiting β-catenin's N-terminal phosphorylation to stabilize the β-catenin-E-cadherin complex. ASPP2 limits the pro-invasive property of oncogenic RAS and inhibits tumour metastasis in vivo. Reduced ASPP2 expression results in EMT, and is associated with poor survival in hepatocellular carcinoma and breast cancer patients. Hence, ASPP2 is a key regulator of epithelial plasticity that connects cell polarity to the suppression of WNT signalling, EMT and tumour metastasis. |
| first_indexed | 2024-03-07T04:35:22Z |
| format | Journal article |
| id | oxford-uuid:cfbd4f76-e0aa-4ba5-9979-bd4f9656f540 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:35:22Z |
| publishDate | 2014 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:cfbd4f76-e0aa-4ba5-9979-bd4f9656f5402022-03-27T07:44:53ZASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cfbd4f76-e0aa-4ba5-9979-bd4f9656f540EnglishSymplectic Elements at OxfordNature Publishing Group2014Wang, YBu, FRoyer, CSerres, SLarkin, JRSoto, MSSibson, NSalter, VFritzsche, FTurnquist, CKoch, SZak, JZhong, SWu, GLiang, AOlofsen, PMoch, HHancock, DDownward, JGoldin, RZhao, JTong, XGuo, YLu, XEpithelial to mesenchymal transition (EMT), and the reverse mesenchymal to epithelial transition (MET), are known examples of epithelial plasticity that are important in kidney development and cancer metastasis. Here we identify ASPP2, a haploinsufficient tumour suppressor, p53 activator and PAR3 binding partner, as a molecular switch of MET and EMT. ASPP2 contributes to MET in mouse kidney in vivo. Mechanistically, ASPP2 induces MET through its PAR3-binding amino-terminus, independently of p53 binding. ASPP2 prevents β-catenin from transactivating ZEB1, directly by forming an ASPP2-β-catenin-E-cadherin ternary complex and indirectly by inhibiting β-catenin's N-terminal phosphorylation to stabilize the β-catenin-E-cadherin complex. ASPP2 limits the pro-invasive property of oncogenic RAS and inhibits tumour metastasis in vivo. Reduced ASPP2 expression results in EMT, and is associated with poor survival in hepatocellular carcinoma and breast cancer patients. Hence, ASPP2 is a key regulator of epithelial plasticity that connects cell polarity to the suppression of WNT signalling, EMT and tumour metastasis. |
| spellingShingle | Wang, Y Bu, F Royer, C Serres, S Larkin, JR Soto, MS Sibson, N Salter, V Fritzsche, F Turnquist, C Koch, S Zak, J Zhong, S Wu, G Liang, A Olofsen, P Moch, H Hancock, D Downward, J Goldin, R Zhao, J Tong, X Guo, Y Lu, X ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1. |
| title | ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1. |
| title_full | ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1. |
| title_fullStr | ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1. |
| title_full_unstemmed | ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1. |
| title_short | ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1. |
| title_sort | aspp2 controls epithelial plasticity and inhibits metastasis through β catenin dependent regulation of zeb1 |
| work_keys_str_mv | AT wangy aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT buf aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT royerc aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT serress aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT larkinjr aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT sotoms aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT sibsonn aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT salterv aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT fritzschef aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT turnquistc aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT kochs aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT zakj aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT zhongs aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT wug aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT lianga aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT olofsenp aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT mochh aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT hancockd aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT downwardj aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT goldinr aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT zhaoj aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT tongx aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT guoy aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 AT lux aspp2controlsepithelialplasticityandinhibitsmetastasisthroughbcatenindependentregulationofzeb1 |